The Prevalence of Hepatitis B Treatment Naive Patients Who Are Not on Treatment, And Associated Complications Among Adults at Bugando Medical Centre, Mwanza.
Material type:
TextPublisher number: Wurzburg Road 35, Premises, Post Code: 33102 | P. O. Box 1464 Mwanza, Tanzania | Phone: (255) 28-298-3384 | Fax: (255) 28-298-3386 |Email: vc@bugando.ac.tz | Website: www.bugando.ac.tz.Language: English Language: Kiswahili Publication details: Mwanza, Tanzania | Catholic University of Health and Allied Sciences [CUHAS-Bugando] | 2024.Description: 33 Pages; Includes ReferencesSubject(s): Summary: Abstract:
Background: Hepatitis B infection is a disease of global significance affecting large number of people. Chronic Hepatitis B (CHB) infection which embraces a large spectrum of the disease remains to be a serious public health problem globally with over 240 million people being affected and causing 650,000 deaths annually [1]. A seroprevalence of HBV infection in the country was reported to be 6% in the general population of Dar es Salaam [6]
Method: The study included records of Medical out-patients’ patients with confirmed Hepatitis B infection at BMC, seen from January 2023 to June 2024, a Systemic random sampling was applied to select study participants who meet inclusion criteria, from the patient records of the hospital.
Results: The current study shows that the prevalence of the Hepatitis B treatment naive patients who are not on treatment is 208 (69.6%) among 299 of the Hepatitis B Positive patients seen at MOPD from January 2023 to June 2024, who were not in treatment related to hepatitis B were recorded to be not medically indicated for hepatitis B treatment 205(98.6%) while others as eligible for medications, prescribed but couldn’t buy 3(1.4%) respectively, of which 168 (56.2%) of patients didn’t have health insurance and all patients who didn’t receive required treatment due to eligible for medications, though couldn’t buy 3(1.4%) didn’t have health insurance 3 (100%), Hepatitis B Treatment naïve who were not in Treatment, 46 (22.1%) had complications, of which 17 (37%) with Portal hypertension, 16(34.8%) Liver cancer, 3(6.5%) Hepatorenal Syndrome, and 1 (2.2%) for Hepatic encephalopathy
Conclusion: The study highlights a significant prevalence of Hepatitis B treatment-naive patients who are not on treatment, with 69.6% of the Hepatitis B positive patients at MOPD from January 2023 to June 2024 being untreated. The primary reason for non-treatment was the lack of medical indication, accounting for 98.6% of the cases. Other included eligible for medications, prescribed but couldn’t buy 3(1.4%), particularly among those without health insurance. The study also identified serious complications among untreated patients, including portal hypertension, liver cancer, renal complications, and hepatic encephalopathy.
| Item type | Current library | Status | Barcode | |
|---|---|---|---|---|
| UNDERGRADUATE DISSERTATIONS | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | Not for loan | 20240904095114.0 |
Abstract:
Background: Hepatitis B infection is a disease of global significance affecting large number of people. Chronic Hepatitis B (CHB) infection which embraces a large spectrum of the disease remains to be a serious public health problem globally with over 240 million people being affected and causing 650,000 deaths annually [1]. A seroprevalence of HBV infection in the country was reported to be 6% in the general population of Dar es Salaam [6]
Method: The study included records of Medical out-patients’ patients with confirmed Hepatitis B infection at BMC, seen from January 2023 to June 2024, a Systemic random sampling was applied to select study participants who meet inclusion criteria, from the patient records of the hospital.
Results: The current study shows that the prevalence of the Hepatitis B treatment naive patients who are not on treatment is 208 (69.6%) among 299 of the Hepatitis B Positive patients seen at MOPD from January 2023 to June 2024, who were not in treatment related to hepatitis B were recorded to be not medically indicated for hepatitis B treatment 205(98.6%) while others as eligible for medications, prescribed but couldn’t buy 3(1.4%) respectively, of which 168 (56.2%) of patients didn’t have health insurance and all patients who didn’t receive required treatment due to eligible for medications, though couldn’t buy 3(1.4%) didn’t have health insurance 3 (100%), Hepatitis B Treatment naïve who were not in Treatment, 46 (22.1%) had complications, of which 17 (37%) with Portal hypertension, 16(34.8%) Liver cancer, 3(6.5%) Hepatorenal Syndrome, and 1 (2.2%) for Hepatic encephalopathy
Conclusion: The study highlights a significant prevalence of Hepatitis B treatment-naive patients who are not on treatment, with 69.6% of the Hepatitis B positive patients at MOPD from January 2023 to June 2024 being untreated. The primary reason for non-treatment was the lack of medical indication, accounting for 98.6% of the cases. Other included eligible for medications, prescribed but couldn’t buy 3(1.4%), particularly among those without health insurance. The study also identified serious complications among untreated patients, including portal hypertension, liver cancer, renal complications, and hepatic encephalopathy.
There are no comments on this title.
Click on an image to view it in the image viewer